Publicacións en colaboración con investigadores/as de Brigham and Women's Hospital (22)

2024

  1. Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement (Nature Reviews Endocrinology, (2023), 19, 12, (722-740), 10.1038/s41574-023-00886-5)

    Nature Reviews Endocrinology

2023

  1. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement

    Nature Reviews Endocrinology, Vol. 19, Núm. 12, pp. 722-740

  2. Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

    Pituitary, Vol. 26, Núm. 5, pp. 583-596

2022

  1. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  2. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Consensus on diagnosis and management of Cushing's disease: a guideline update

    The lancet. Diabetes & endocrinology, Vol. 9, Núm. 12, pp. 847-875

  2. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

    Journal of the Endocrine Society, Vol. 5, Núm. 3

2020

  1. Multidisciplinary management of acromegaly: A consensus

    Reviews in Endocrine and Metabolic Disorders, Vol. 21, Núm. 4, pp. 667-678

2019

  1. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357

  2. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  3. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

  4. Treatment of Diabetes in Older Adults: An Endocrine Society

    Journal of Clinical Endocrinology and Metabolism, Vol. 104, Núm. 5, pp. 1520-1574

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

  2. Correction to: Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement (Pituitary, (2017), 20, 5, (489-498), 10.1007/s11102-017-0838-2)

    Pituitary

2017

  1. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

    Journal of the American College of Cardiology, Vol. 69, Núm. 2, pp. 176-185

  2. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  3. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

    Pituitary, Vol. 20, Núm. 5, pp. 489-498

  4. Evolocumab and clinical outcomes in patients with cardiovascular disease

    New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722

2015

  1. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation

    Circulation: Cardiovascular Quality and Outcomes, Vol. 8, pp. S12-S20

  2. Ghrelin

    Molecular Metabolism, Vol. 4, Núm. 6, pp. 437-460